Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib
| Autor: | Satoshi Matsuo, Satsuki Hashimoto, Ryu Sasaki, Toshihisa Matsuzaki, Yasuhide Motoyoshi, Noboru Kinoshita, Kazuo Ohba, Satoshi Miuma, Hidetaka Shibata, Hiroshi Yatsuhashi, Kazuhiko Nakao, Susumu Eguchi, Hisamitsu Miyaaki, Yuji Kato, Yuki Kugiyama, Masafumi Haraguchi, Masaaki Hidaka, Masanori Fukushima, Masaya Shigeno, Shinichi Iwatsu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Gastroenterology chemistry.chemical_compound Older patients Liver Function Tests Internal medicine Medicine Humans In patient Age of Onset Aged Retrospective Studies Aged 80 and over business.industry Phenylurea Compounds Liver Neoplasms Age Factors General Medicine Odds ratio medicine.disease Confidence interval Oncology chemistry Liver Hepatocellular carcinoma Quinolines Observational study Female Liver function business Lenvatinib |
| Zdroj: | Anticancer research. 41(4) |
| ISSN: | 1791-7530 |
| Popis: | Background The age of patients with advanced hepatocellular carcinoma (HCC) eligible for molecular-targeted drug treatment is increasing. We assessed liver function after lenvatinib administration according to age in patients with advanced HCC. Patients and methods In this retrospective, multicenter, observational study, we reviewed the records of patients with HCC who received lenvatinib treatment (March 2018-March 2020). Liver function was measured using the Albumin-Bilirubin Index (ALBI). Results Of 119 patients, with a median age of 72.0 years, median overall survival was 15.3 months. Overall survival was significantly better in the group which maintained liver function (p=0.02). Older age (≥72 years) was associated with liver-function deterioration within 8 weeks (odds ratio=2.47, 95% confidence interval=1.06-5.75, p=0.035). The ALBI score was significantly higher in the older group at 4 and 8 weeks after lenvatinib administration. Conclusion Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|